Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23348734.
- Also identified by DOI 10.1172/JCI67589 and PMC identifier 3561839.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The major constituent of green tea, (-)-epigallocatechin-3-O-gallate (EGCG), has been shown to have cancer-preventive and therapeutic activities. Numerous molecular targets for EGCG have been proposed, but the mechanisms of its anticancer activities are not clearly understood. In this issue of the JCI, Kumazoe et al. report that EGCG activates 67-kDa laminin receptor (67LR), elevates cGMP levels, and induces cancer cell apoptosis. Furthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes with EGCG to induce cancer cell death. This is a provocative observation with important implications for cancer therapy. It also raises several issues for further investigation, such as the mechanism by which EGCG specifically activates 67LR.
Medical subject headings
- Apoptosis
- Cyclic GMP
- Neoplasms
- Receptors, Laminin